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Immunotherapy with CD123-specific T-cell engager pro-
teins or with T cells expressing CD123-specific chimeric 
antigen receptors is actively being pursued for acute 
myeloid leukemia. T cells secreting bispecific engager 
molecules (ENG-T cells) may present a promising alter-
native to these approaches. To evaluate therapeutic 
potential, we generated T cells to secrete CD123/CD3-
bispecific engager molecules. CD123-ENG T cells recog-
nized primary acute myeloid leukemia (AML) cells and 
cell lines in an antigen-dependent manner as judged by 
cytokine production and/or tumor killing, and redirected 
bystander T cells to AML cells. Infusion of CD123-ENG 
T cells resulted in regression of AML in xenograft mod-
els conferring a significant survival advantage of treated 
mice in comparison to mice that received control T cells. 
At high effector to target ratios, CD123-ENG T cells rec-
ognized normal hematopoietic stem and progenitor cells 
(HSPCs) with preferential recognition of HSPCs from cord 
blood compared to bone marrow. We therefore intro-
duced the CD20 suicide gene that can be targeted in vivo 
with rituximab into CD123-ENG T cells. The expres-
sion of CD20 did not diminish the anti-AML activity of 
CD123-ENG T cells, but allowed for rituximab-mediated 
ENG-T cell elimination. Thus, ENG-T cells coexpressing 
CD20 suicide and CD123 engager molecules may pres-
ent a promising immunotherapeutic approach for AML.
Received 4 November 2015; accepted 1 June 2016; advance online  
publication 12 July 2016. doi:10.1038/mt.2016.116
INTRODUCTION
The outcome for pediatric and adult patients with acute myeloid 
leukemia (AML) remains poor, particularly in those with high risk 
or relapsed disease.1–3 Additionally, current treatment protocols 
heavily rely on chemotherapeutic agents whose use commonly 
leads to serious acute and long-term toxicities. Given this, there is 
a need to develop novel targeted therapies that improve outcomes 
and reduce treatment-related complications of current therapies.
The ex vivo preparation of antigen-specific T cells followed by 
their adoptive transfer is one attractive strategy to improve out-
comes for hematological malignancies, since T-cell killing does 
not rely on the broadly cytotoxic mechanisms of conventional 
therapies.4–7 Indeed the adoptive transfer of T cells that are geneti-
cally modified with CD19-specific chimeric antigen receptors 
(CARs) has resulted in impressive clinical responses; especially 
in patients with acute lymphoblastic leukemia.8–15 However, for 
AML, there has been limited success. Lewis Y (LeY)-specific CAR 
T cells have been tested so far in one clinical study without robust 
response.16 In addition, CD33-specific CAR T cells were evalu-
ated in a single patient with limited success.17 Several groups have 
explored interleukin-3 receptor alpha (IL3Rα, CD123)-specific 
CAR T cells for AML in preclinical models, and while these cells 
had potent antitumor activity, one group demonstrated that nor-
mal hematopoietic stem and progenitor cells (HSPCs) are also 
eliminated.18–22
We and others have developed an alternative strategy to gener-
ate tumor-specific T cells by genetic modification with diabodies,23 
or secretable, bispecific T-cell engager molecules, which consist of 
two single chain variable fragments (scFVs) specific for a tumor-
associated antigen and CD3ε (ENG-T cells).24 These T cells not 
only recognize and kill tumor cells in a tumor-associated antigen-
dependent manner, but also have the unique ability to redirect 
bystander T cells to tumor cells.24 Consistent synthesis of engagers 
by adoptively transferred T cells should be superior to the direct 
infusion of the recombinant bispecific antibody, because these 
typically have short half-lives and do not accumulate at tumor 
sites.
Here, we report the development of CD123-ENG T cells and 
demonstrate that these ENG-T cells recognize and kill CD123-
positive target cells in vitro, redirect bystander T cells, and have 
potent antitumor activity in vivo. Since CD123-ENG T cells rec-
ognized normal HSPCs at high effector to target ratios, we further 
genetically modified CD123-ENG T cells to also include the CD20 
suicide gene (CD20.CD123-ENG T cells).25–27 CD20.CD123-ENG 
T cells had equivalent effector function in comparison to CD123-
ENG T cells and were readily killed in the presence of rituximab 
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and complement making them a promising T-cell therapy “candi-
date” for future clinical development.
RESULTS
Generation of CD123-ENG T cells
CD123-ENG T cells were generated by transduction with an 
RD114-pseudotyped retroviral vector encoding a bispecific 
CD123-CD3 engager molecule, an internal ribosomal entry site 
(IRES), and mOrange (Figure  1a). Transduction of T cells was 
confirmed by fluorescence-activated cell sorting (FACS) analysis 
for mOrange expression. Mean transduction efficiency was 79.2% 
(range: 62.5–95.5%; n = 14; Figure 1b,c). Phenotypic analysis of 
transduced T cells revealed a mixture of CD4- and CD8-positive 
T  cells, with reproducible percentages of naive, central memory, 
and effector memory cell populations (Supplementary Figure S1, 
n = 5). Transduction of cells and expression of CD123-ENG did not 
alter the T-cell phenotype in comparison to nontransduced (NT) 
T cells activated and expanded in parallel. CD123-ENG secretion 
and binding to both transduced and NT T cells was confirmed by 
FACS analysis using an anti-mouse F(ab’)2 (Figure 1d). To quan-
tify CD123-ENG protein in cell culture media, we developed an 
enzyme-linked immunosorbent assay (ELISA) using recombinant 
CD123 T-cell ENG protein as a standard (Supplementary Figure 
S2). CD123 T-cell ENG protein was readily detected in medium 
conditioned by CD123-ENG T cells (mean: 7.5 µg/ml, 95% CI: 
4.0–11.1 µg/ml) in contrast to medium conditioned by T cells 
expressing CD19 T-cell ENG protein (CD19-ENG T cells; mean: 
9.8 ng/ml, 95% CI: 0–26.06 ng/ml) confirming specificity of the 
developed assay (Figure 1e).
CD123-ENG T cells recognize and kill CD123-positive 
AML cells in vitro
To demonstrate the specificity of CD123-ENG T cells against 
tumor cells expressing the antigen target, we used a panel of 
CD123-positive (K562-CD123, KG1a, MV-4–11, MOLM-13) and 
CD123-negative (K562) cell lines (Supplementary Figure S3). 
We performed coculture assays with these tumor cells and ENG 
T cells targeting CD123 or an irrelevant antigen not expressed 
on cell targets (CD19). CD123-ENG T cells secreted significant 
amounts of IFNγ and IL-2 when exposed to cells expressing 
CD123 (Figure 2a,b). In contrast, coculture with CD123-negative 
cells did not induce cytokine production. Similarly, CD19-ENG 
T cells did not produce cytokine when cocultured with target cells 
(Figure 2a,b). To further confirm specificity, we assessed the kill-
ing potential of CD123-ENG T cells against CD123-positive target 
cells in a 4-hour chromium release cytotoxicity assay. CD123-
ENG T cells effectively lysed AML cells expressing CD123, but 
did not kill the CD123-negative K562 cell line (Figure 2c). CD19-
ENG T cells did not have any cytolytic activity against the tested 
cell lines, confirming specificity.
CD123-ENG T cells redirect bystander T cells to 
CD123-positive AML cells in vitro
To examine the potential of ENG T cells to activate bystander cells 
in vitro, we performed transwell assays with insert wells that allow 
the diffusion of molecules but not the migration of cells. ENG 
T cells were plated in the insert well and KG1a target cells with NT 
T cells in the bottom well. Only CD123-ENG T cells, in contrast to 
NT T cells and CD19-ENG T cells, were able to induce significant 
target killing by NT T cells (Figure 3a). No tumor cell killing was 
observed in wells that contained only target cells without T cells, 
indicating that engager protein alone is inherently nontoxic. We 
confirmed the ability of CD123-ENG T cells to redirect T cells 
that had not been expanded ex vivo by repeating the experiment 
with peripheral blood mononuclear cells (PBMCs) as a source of 
bystander T cells in the bottom well (Figure 3b).
CD123-ENG T cells kill primary AML blasts in vitro
To further assess the potential translational impact of CD123-
ENG T cells as a treatment for AML patients, we tested their 
cytolytic activity against primary AML blasts. Pediatric AML 
samples were collected, and first evaluated for CD123 expression 
(Figure 4a). The blast percentage recorded by our clinical hema-
topathology laboratory and further described in the methods sec-
tion was AML#1: 33%, AML#2: 90%, and AML#3: 65%. Primary 
samples were then treated with CD123- or CD19-ENG T cells 
at an E:T ratio of 1:1 or 1:10 prior to plating in semisolid media 
with growth factors present. Untreated samples served as controls. 
After 10–14 days of culture, cells were counted. At both E:T ratios 
tested CD123-ENG T cells induced significant AML blast killing 
in comparison to CD19-ENG T cells (Figure 4b, P < 0.05).
CD123-ENG T cells have anti-AML activity in vivo
We evaluated the anti-AML activity of CD123-ENG T cells in our 
MOLM-13 AML NSG xenograft model. Post sublethal irradia-
tion, mice were injected with MOLM-13.GFP.ffLuc cells and on 
day 7 and 14 received an intravenous injection of CD19-ENG or 
CD123-ENG T cells. Untreated mice served as controls. Within 
4  days post the first T-cell injection mice treated with CD123-
ENG T cells had a significant decline in their bioluminescence 
signal (P < 0.001) with subsequent leukemia eradication in all 
treated mice (Figure 5a,d). In contrast, untreated mice and mice 
treated with CD19-ENG T cells had a significant increase (P < 
0.002) in their bioluminescence signal (Figure 5b,c) and died 
of progressive disease by day 20 (Figure 5e). While none of the 
CD123-ENG T-cell treated mice developed recurrent leukemia, 
4/5 mice died 29 (×2), 46, and 67 days post-tumor cell injec-
tion. The cause of death was xenogeneic graft versus host disease 
(GVHD) as commonly reported with adoptive transfer of human 
T cells in the NSG murine model.28,29 We confirmed this for 1/4 
mice by demonstrating human T-cell infiltration throughout the 
liver (Supplementary Figure S4A).
To assess the contribution of target antigen-specific CD123-
ENG T-cell stimulation in inducing GVHD, MOLM-13 bearing 
and control mice were injected on day 7 with 1 × 107 CD123-ENG 
T cells that were also genetically modified to express GFP.ffLuc. 
While in control mice there was a rapid, significant decline 
(P < 0.05) of infused T cells, no significant decline of CD123-ENG 
T cells was observed for 5 days postinfusion in MOLM-13 bearing 
mice (Figure 6a,b). Mice were euthanized on day 6 to determine 
the presence of human T cells (human CD3 and CD45 positive) 
and CD123-ENG expressing human T cells (mOrange positive) 
in spleen and bone marrow. The average frequency of human 
T cells was 1.1% (range: 0.52–2.27%) in spleens and 0.3% (range: 
1616 www.moleculartherapy.org vol. 24 no. 9 sep. 2016
© The American Society of Gene & Cell Therapy
CD123-Engager T Cells for the Treatment of AML
Figure 1  Generation of CD123-ENG T cells. (a) Schematic of retroviral vector encoding CD123-ENG and mOrange. (b,c) Representative FACS 
diagram and summary data (CD123-ENG T cells (n = 14), NT T cells (n = 6) of mOrange expression post-transduction. (d) A mouse F(ab’)2 antibody 
was used to detect cell surface-bound CD123 T-cell ENG protein. mOrange-positive and -negative T cells stained positive (filled curve) for CD123 
T-cell ENG in contrast to samples that were stained with isotype alone (open curve). NT T cells cultured without CD123-ENG T cells did not stain 
positive with the mouse F(ab’)2 antibody, confirming specificity. (e) Detection of CD123 T-cell ENG protein in media of CD123-ENG and CD19-ENG 
T cells after 24 hours of culture (n = 4, performed in triplicates, box graph, whiskers: min, max, CD123-ENG versus CD19-ENG T cells P < 0.001).
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Figure 2 CD123-ENG T cells recognize and kill CD123-positive acute myeloid leukemia cells. (a, b) CD123-ENG or CD19-ENG T cells were 
cocultured with CD123-positive (K562-CD123, MV-4-11, MOLM-13, KG1a) or -negative (K562) cell lines. After 24 hours, (a) IFNγ or (b) IL-2 was 
determined by ELISA (n = 3–4, assay performed in duplicates; CD123-ENG versus CD19-ENG: *P < 0.05, **P < 0.01, ***P < 0.001). (C) Cytotoxicity 
assays were performed using CD123-ENG or CD19-ENG T cells as effectors and CD123-positive (K562-CD123, MV-4-11, KG1a) or -negative (K562) 
cell lines as targets at a E:T ratio of 10:1 (mean + SD; n = 4; assay was performed in triplicates, *P < 0.02, **P < 0.002).
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0.27–0.37%) in bone marrows with no significant difference 
between control and MOLM-13 bearing mice (Figure 6c). In the 
infused CD123-ENG T-cell product 50.7% of cells were mOrange 
positive. On average 56.3% (range: 53.0–59.8%) of human T cells 
from spleens and 57.3% (range: 54.3–63.2%) of human T cells 
from bone marrows were positive for mOrange (CD123-ENG T 
cells) with no significant difference between control and MOLM-
13 bearing mice, and no significant difference to the infused T-cell 
product (Figure 6d). Residual MOLM-13 cells were not detect-
able in spleens and bone marrows of mice that had been injected 
with MOLM-13 as judged by FACS analysis of CD123 (data not 
shown).
Toxicity of CD123-ENG T cells against hematopoietic 
stem and progenitor cells 
Given the reported low level of expression of CD123 on HSPCs, 
we sought to determine if CD123-ENG T cells recognize this cell 
population.30,31 We used cord blood or bone marrow as a source of 
HSPCs. Samples were treated with CD123- or CD19-ENG T cells 
at E:T ratios of 5:1, 1:1, or 1:10 prior to plating in semisolid media 
with growth factors present. Untreated samples served as controls. 
After 10–14 days, colony forming unit (CFUs) were counted. At 
an E:T ratio of 5:1, significant toxicity was observed (Figure 7a,b). 
At an E:T ratio of 1:1 or 1:10, toxicity was dependent on the stem 
cell source with umbilical cord- derived HSPCs being more sensi-
tive to CD123-ENG T cells than bone marrow-derived HSPCs.
CD123-ENG T cells expressing the CD20 suicide gene 
retain their anti-AML activity and are eliminated in 
the presence of rituximab and complement
While CD123-ENG T cells had potent anti-AML activity, they 
induced killing of normal HSPCs at high E:T ratios, indicating that 
CD123-ENG T cells should also express a suicide gene to allow 
their selective depletion in the event of unwanted side effects. 
We focused on transgenic expression of CD20, which allows the 
depletion of T cells by the FDA-approved CD20 monoclonal anti-
body rituximab via complement-mediated or antibody-dependent 
cell-mediated cytotoxicity. To coexpress CD20 and CD123 T-cell 
ENG molecules in T cells, we generated a retroviral vector encod-
ing CD20, a 2A sequence, and our CD123-ENG (CD20.CD123-
ENG; Supplementary Figure S5A). CD20.CD123 ENG T cells 
were generated by retroviral transduction and a mean of 60.3% 
(range: 42.5–73.5%, n = 8, Supplementary Figure S5B) of T cells 
were genetically modified as judged by FACS analysis for CD20. 
There was no change in the percentage of CD20-positive T cells 
early (day 3–5) versus late (day 13–15) post-transduction, indicat-
ing that transgene expression is stable over time (Supplementary 
Figure S5C). We observed no difference in the cytolytic activ-
ity between CD123-ENG T cells and CD20.CD123-ENG T cells 
(Figure 8a, P = 0.450). In vivo, in the MOLM-13 AML NSG xeno-
graft model, a single dose of 1 × 107 CD20.CD123-ENG T cells had 
similar antitumor activity (Figure 8b) as CD123-ENG T cells in 
the previously performed experiment (Figure 5d).
To evaluate the functionality of the CD20 suicide gene, we 
performed a cytotoxicity assay with 51Cr-labeled NT, CD123-
ENG, or CD20.CD123-ENG T cells in the presence of rituximab 
and/or complement. While complement or rituximab alone 
induced <20% killing of CD20.CD123-ENG T cells, ~60% kill-
ing was observed in the presence of rituximab and complement 
in a 4-hour chromium release assay (Figure 8c). Since the mean 
transduction efficiency of CD20.CD123-ENG T-cell lines was 
60.3% (range: 42.5–73.5%) in the performed assays, these results 
demonstrate >95% killing of transduced T cells in the pres-
ence of rituximab and complement. These findings were con-
firmed in a 4-hour chromium release assay using CD20-selected 
CD20.CD123-ENG T cells (Supplementary Figure S6A,B). 
In contrast, rituximab and complement had no cytolytic activ-
ity against NT or CD123-ENG T cells. To determine the dura-
bility of rituximab/complement-mediated killing of CD20.
CD123-ENG T cells in a cell culture assay, CD20.CD123-ENG 
T cells were treated with rituximab/complement for two hours, 
Figure 3 CD123-ENG T cells activate bystander T cells and freshly iso-
lated peripheral blood mononuclear cells (PBMCs) against CD123-
positive target cells. (a) 1 × 106 MOLM-13.GFP.ffLuc cells were plated in 
the bottom well with or without 1 × 106 NT T cells. Control (NT, CD19-
ENG) or CD123-ENG T cells were plated in the insert well at the indi-
cated T-cell dose. Following 24-hour incubation, viable MOLM-13.GFP.
ffLuc cells were quantified by luciferase assay (n = 3; assay was performed 
in duplicates; for CD123-ENG: 106 ENG-T cells in insert, 106 NT T cells 
in bottom well versus 106 ENG-T cells in insert, no NT T cells in bottom 
well: P < 0.005, 105 ENG-T cells in insert, 106 NT T cells in bottom well 
versus 106 ENG-T cells in insert, no NT T cells in bottom well: P < 0.05). 
(b) 1 × 106 MOLM-13.GFP.ffLuc cells were plated in the bottom well with 
or without 5 × 106 PBMCs. 1 × 106 autologous NT, CD19-ENG, or CD123-
ENG T cells were plated in the insert well. Following 24-hour incubation, 
viable MOLM-13.GFP.ffLuc cells were quantified by luciferase assay (n=3; 
assay was performed in triplicates; for CD123-ENG: PBMCs versus no 
PBMCs: P < 0.02).
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washed, and the surviving T cells cultured for 7 days. Greater 
than 90% of CD20.CD123-ENG T cells were killed as judged 
by FACS analysis (Figure 8d, n = 5, P < 0.001). In contrast, no 
significant killing of CD20-positive cells was observed in the 
presence of rituximab or complement alone, when compared 
to untreated cells. Concurrent with FACS analysis, a standard 
chromium release cytotoxicity assay was performed using KG1a 
as targets and untreated or rituximab/complement-treated 
CD20.CD123-ENG T-cell lines as effectors, one week after treat-
ment. CD19-ENG T-cell lines served as negative, and CD123-
ENG T-cell lines as positive controls. While untreated CD20.
CD123-ENG T-cell lines readily killed KG1a cells, rituximab/
complement-treated CD20.CD123-ENG T-cell lines did not, 
indicating successful depletion of CD20.CD123-ENG T cells 
(Figure 8e). Having established the functionality of the CD20 
suicide gene in vitro, we assessed the ability of rituximab to 
deplete CD20.CD123-ENG T cells in vivo. Post sublethal irra-
diation, mice were injected with MOLM-13 cells, and on day 7 
received 3 × 106 CD20.CD123-ENG T cells that were also geneti-
cally modified with GFP.ffLuc, and selected for CD20 expression 
(Supplementary Figure S6A). Starting day 3 post-T-cell infu-
sion, mice received intraperitoneal injection (IP) of 250 µg ritux-
imab for 3 consecutive days. Rituximab administration resulted 
in a greater than 90% decrease in the bioluminescence signal, 
demonstrating the effectiveness of rituximab to destroy CD20.
CD123-ENG T cells in vivo. (Figure  8f, rituximab versus no 
treatment: P < 0.05 starting day 2 post-first dose of rituximab).
DISCUSSION
Herein, we describe the generation of CD123-ENG T cells and 
demonstrate that these cells recognize and kill CD123-positive 
target cells in an antigen-dependent manner, redirect “bystander” 
T cells to CD123-positive target cells, and have potent antitu-
mor activity in vivo. We also observed killing of HSPCs at high 
effector to target ratios, and therefore combined the expression 
of CD123-ENG molecules with a CD20 suicide gene in T cells. 
CD20.CD123-ENG T cells retained their antileukemia activity 
and could be readily depleted in the presence of rituximab and 
complement.
T-cell immunotherapy as a less toxic, precision therapy for 
the treatment of leukemia is a therapeutic approach that has 
enjoyed recent popularity due to the success of CD19-CAR T cells 
administered for refractory acute lymphoblastic leukemia.8–15 In 
contrast to CAR T-cell therapy for acute lymphoblastic leukemia, 
CAR T-cells targeting AML have not been extensively tested in 
the clinic. However, several antigens are currently being actively 
explored in preclinical studies including CD33, CD44v6, CD123, 
and LeY.16–22,32–36 While all of these antigens have been targeted 
with CAR T cells, none has been targeted with ENG T cells, 
which are a new class of T cells with the unique ability to redirect 
bystander T cells to tumor cells in an antigen dependent fashion.24
CD123-ENG T cells not only killed AML cell lines but also 
primary AML blasts in vitro, confirming studies by others that 
CD123-positive AML cells can be targeted with genetically modi-
fied T cells.18–22 While all previous studies used T cells expressing 
Figure 4 Primary AML cells are killed by CD123-ENG T cells in vitro. (a) FACS analysis of pediatric primary acute myeloid leukemia (AML) samples 
for CD123 expression. AML blasts,(CD33+, CD3-, CD19- (data not shown for CD19)) were analyzed for CD123 expression (filled curve: isotype 
control; open curve: CD123 MAb). (b) Primary AML samples were treated with CD19-ENG or CD123-ENG T cells at E:T ratios of 1:1 and 1:10 for 
6 hours. Following coculture, cells were plated in MethoCult media and incubated for 10–14 days. Final cell counts are displayed as percentage of 
control; n = 3; CD19-ENG versus CD123-ENG T cells: *P < 0.05.
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CD123-CARs, which cannot activate bystander T cells against 
AML cells, we show here that ENG T cells readily redirect 
unmodified bystander T cells to CD123-positive target cells. Since 
the efficacy of CAR T-cell therapy relies on significant in  vivo 
expansion of T cells, the observed “bystander effect” might allow 
for disease control with limited in vivo expansion of adoptively 
transferred T cells. We have shown in vivo that the short-term 
persistence of CD123-ENG T cells is significantly impacted by 
the presence of the antigen target. In our model system, the ratio 
of CD123-ENG expressing to unmodified human T cells is main-
tained, suggesting equal stimulation of CD123-ENG and unmod-
ified cells. This indicates that ENG T cells have the capability of 
Figure 5 CD123-ENG T cells have potent anti-acute myeloid leukemia activity in vivo. Antitumor activity of CD123-ENG T cells in MOLM-13 
leukemia NSG xenograft model. MOLM-13.GFP.ffLuc-bearing mice received an i.v. dose of 1 × 107 CD123-ENG (n = 5) or CD19-ENG T cells (n = 5) 
on day 7 and 14 post-tumor cell injection. Untreated animals served as controls (n = 10). Tumor growth was followed by bioluminescence imaging. 
(a) Representative images of animals (day post-tumor cell injection is shown in the upper right corner of images). (b–d) Quantitative bioluminescence 
imaging results (dotted lines: individual mice; solid lines: median; radiance=photons/sec/cm2/sr). Starting day 3 post-first T-cell injection for CD123-
ENG versus CD19-ENG T cells, and CD123-ENG T cells versus untreated: P < 0.001). (e) Kaplan-Meier survival curve (control versus CD123-ENG 
T cells: P = 0.0004; control versus CD19-ENG T cells: NS; CD123-ENG versus CD19-ENG T cells: P = 0.0015).
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activating 100% of infused T cells, potentially overcoming lower 
transduction efficiencies of patients’ T cells. We observed xeno-
genic GVHD in treated mice. In our in vivo CD123-ENG T-cell 
persistence studies we only observed a significant difference in 
the frequency of CD123-ENG T cells between MOLM-13 bear-
ing mice and control mice for the first 5 days after injection. Thus 
GVHD in our model is most likely due to nonspecific xenogenic 
T-cell stimulation at later time points post-infusion as observed 
by others.28,29
CD123-ENG molecules induced significant IL-2 production 
in an antigen-dependent manner without having a costimula-
tory domain. While AML blasts do not express standard costim-
ulatory molecules such as CD80,37 they express for example 
NKG2D ligands,38 which can provide costimulation39 explaining 
the observed IL-2 production. One potential advantage of ENG 
T cells versus the infusion of bispecific antibodies is that T cells 
can traffic to tumor sites and produce ENG molecules locally. We 
could not demonstrate this advantage in the described systemic 
AML model, but have shown ENG T-cell homing to tumor sites 
in a local B-cell malignancy model.40 Bispecific antibodies such as 
blinatumomab that consist of 2 scFvs have a half-life of 2 hours 
in vivo.41 Since half-life depends on molecular weight, we expect 
that scFv-based ENG molecules secreted from T cells will have a 
similar half-life.
CD123 is expressed at low levels on plasmacytoid dendritic 
cells, basophils, monocytes, endothelial cells, and HSPCs.30,42,43 
Figure 6 Antigen-specific persistence of CD123-ENG T cells in vivo. MOLM-13 bearing or control mice were injected I.V. with 1 × 107 CD123-ENG.
mOrange T cells that were also genetically modified to express GFP.ffLuc (n = 5 per group). (a) Images of individual mice. (b) Quantitative biolumines-
cence imaging results (radiance = photons/sec/cm2/sr, mean and SD is plotted, *P < 0.001, **P < 0.0001). (c, d) On day 6 post-T-cell injection, mice were 
euthanized and spleens and bone marrows (both femurs) of all (5) acute myeloid leukemia (AML)-bearing mice and of two control mice that received 
CD123-ENG T cells were processed for FACS analysis. (c) Percentage of human T cells (CD45-positive, CD3-positive) gated on live cells (AML-bearing 
mice versus control mice: P = NS). (d) mOrange-positive cells (%) gated on human T cells (CD45-positive, CD3-positive); dotted line: mOrange-positive 
cells (%) in infused CD123-ENG T cells (AML- bearing mice versus control mice: P = NS; % mOrange positive cells in infused CD123-ENG T cells versus % 
mOrange-positive T cells on day 6 postinfusion: P = NS).
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Controversy exists in regards to the recognition of normal HSPCs 
by CD123-CAR T cells. While one group demonstrated that the 
infusion of CD123-CAR T cells inhibited the engraftment of fetal 
liver- or bone marrow-derived HSPCs in NSG mice,21,22 two groups 
reported limited toxicity of CD123-CAR T cells.18–20 Limited toxic-
ity has also been observed for a CD123/CD3-specific dual affinity 
retargeting recombinant protein. In a non-human primate model, 
CD123/CD3-specific dual affinity retargeting induced a cytokine 
release syndrome (CRS) with the first infusion and a transient 
decrease in hematocrit after multiple infusions.44 Here we show that 
the toxicity of CD123-ENG T cells depends on the used E:T ratio 
as well as the source of the HSPCs in CFU assays. We did not dif-
ferentiate between lineage-specific CFUs since we wanted to assess 
the ‘global toxicity’ on normal HSPCs of CD123-ENG T cells. We 
are planning to determine the effects on lineage-specific CFUs in 
the future. We observed that HSPCs derived from cord blood were 
more sensitive to CD123-ENG T-cell mediated killing than HSPCs 
derived from bone marrow. Others have reported that the percent-
age of HSPCs expressing CD123 as well as the expressed level of 
CD123 is higher in cord blood than bone marrow derived HSPCs, 
which supports our findings.45 While high ratios caused signifi-
cant killing of HSPCs, limited killing was observed at low ratios at 
which AML blasts were still killed. These results suggest that there 
may be a “therapeutic window”, which would allow the killing of 
AML blasts, while sparing normal HSPCs.
Since it is impossible to predict the effective E:T ratio in vivo, 
we reasoned that introducing a ‘suicide gene’ into CD123-ENG 
T cells would be advisable for future clinical development. We first 
evaluated the inducible caspase 9 suicide gene in CD123-ENG 
T cells, but observed baseline toxicity (Supplementary Figure S7). 
We next focused on expressing CD20 in T cells in combination 
with rituximab administration as a “suicide gene” approach,25–27 
since antibodies can travel freely through the sinusoidal clefts that 
are present in bone marrow,46 the site of potential HSPC toxicity. 
CD20.CD123-ENG T cells had stable CD20 expression, compa-
rable antitumor activity in vitro and in vivo, and were readily elimi-
nated by rituximab in the presence of complement in vitro. We also 
showed that rituximab administration in vivo resulted in a greater 
than 90% depletion of CD20.CD123-ENG/GFP.ffLuc T cells as 
judged by bioluminescence imaging in MOLM-13-bearing NSG 
mice. Of note, NSG mice have deficient complement pathways.47 
Thus the observed in vivo T-cell killing in these mice relies mainly 
on FC-receptor mediated killing. In humans, which have an intact 
complement pathway as well as FC-receptor mediated killing, we 
expect rituximab to even be more effective in depleting CD20-
positive T cells. Thus, our in vitro and in vivo results indicate that 
CD20 expression in combination with rituximab administration is 
a suitable suicide gene method to eliminate CD123-ENG T cells. 
Nevertheless, to move our approach to clinical application, we pro-
pose to perform first-in-human studies in the pretransplant set-
ting. We aim to use CD20.CD123-ENG T cells to induce complete 
remission in refractory AML patients who have an identified stem 
cell donor, before proceeding to an allogeneic stem cell transplant. 
Our approach is comparable to the strategy taken by other inves-
tigators who have open clinical studies with CD123-CAR T cells 
(NCT02159495, NCT02623582), and is expected to mitigate the 
risk of long-term aplasia and graft failure from all CD123-targeted 
T-cell therapies, including CD123-ENG T cells.
In summary, our study demonstrates that CD20.CD123-ENG 
T cells have potent antitumor activity, redirect bystander T cells 
to CD123-positive AML, and are readily eliminated by rituximab/
complement. Thus, CD20.CD123-ENG T cells may be a prom-
ising alternative to current CD123-targeted immunotherapy 
approaches that either rely on the continuous infusion of recom-
binant protein or the adoptive transfer of CAR T cells.
MATERIALS AND METHODS
Cells and culture conditions. 293T, K562, KG1a, and MV-4-11 cell lines 
were purchased from the American Type Culture Collection (ATCC, 
Manassas, VA) and cultured in Dulbecco's Modified Eagle Medium 
(DMEM, ThermoScientific, Waltham, MA) supplemented with 2 mmol/l 
Glutamax (Invitrogen, Carlsbad, CA) and 10% Fetal Bovine Serum (FBS, 
ThermoScientific (293T)) or Roswell Park Memorial Institute (RPMI, 
ThermoScientific), supplemented with 2 mmol/l Glutamax and 10% (K562) 
or 20% (MV-4–11) FBS or scove's Modified Dulbecco's Medium (IMDM, 
ThermoScientific) supplemented with 2 mmol/l Glutamax and 20% Fetal 
Bovine Serum (FBS) FBS (KG1a). MOLM-13 cell line was purchased from 
the Leibniz Institute (DSMZ, German Collection of Microoganisms and Cell 
Cultures, Braunschweig, Germany) and cultured in RPMI supplemented 
Figure 7 CD123-ENG T cells recognize HSPCs at high effector to target ratios. Bone marrow mononuclear cells (BMMCs) or cord blood mono-
nuclear cells (CBMCs) were cultured of E:T ratios of 5:1, 1:1, and 1:10 with CD19-ENG or CD123-ENG T cells for 6 hours. Cells were plated in 
MethoCult media and CFUs were counted after 10–14 days. Box graph, whiskers: min, max. (a) BMMCs: n = 4; CD123-ENG versus CD19-ENG T cells: 
5:1 P = 0.001, 1:1 P = ns, and 1:10 P = ns. (b) CBMCs: n = 4; CD123-ENG versus CD19- ENG T cells: 5:1 P < 0.001, 1:1 P < 0.001, and 1:10 P < 0.02.
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with 2  mmol/l Glutamax and 10% FBS. All cells were maintained in a 
humidified atmosphere containing 5% CO2 at 37 °C. K562 cells expressing 
CD123 (K562.CD123) were generated by transducing K562 cells with a len-
tiviral vector encoding CD123 and a green fluorescent protein/puromycin 
resistance gene (GFPpuro; pCDH.CMV.CD123.EF1.GFPpuro). MOLM-13 
cells expressing an enhanced GFP firefly luciferase fusion gene (MOLM-13.
GFP.ffLuc) were generated by transducing MOLM-13 cells with a retroviral 
vector encoding GFP.ffLuc.48 GFP-positive cells were sorted and maintained 
in RPMI supplemented with 2 mmol/l Glutamax and 10% FBS. Luciferase 
expression was confirmed using D-luciferin.
Figure 8 CD20 gene-modified CD123-ENG T cells retain their effector function against CD123-positive acute myeloid leukemia and are effec-
tively eliminated by rituximab. (a) Cytotoxicity assays were performed using CD123-ENG, CD20.CD123-ENG, or CD19-ENG T cells as effectors and 
KG1a as CD123-positive target. (n = 3; assay was performed in triplicates, P = 0.450, CD123-ENG versus CD20.CD123-ENG T cells). (b) MOLM-13.
GFP.ffLuc-bearing mice received an i.v. dose of 1 × 107 CD20.CD123-ENG T cells on day 7 post-tumor cell injection. Quantitative bioluminescence 
imaging results (dotted lines: individual mice; solid line: median; radiance = photons/sec/cm2/sr). (c) CD20.CD123-ENG, CD123-ENG, or NT T cells 
were labeled with 51Chromium and treated with rituximab and/or complement in a standard cytotoxicity assay. (n = 4; assay was performed in 
triplicate; for CD20.CD123-ENG T cells: untreated versus rituximab and complement: P = 0.003). (d, e) CD20.CD123-ENG T cells were treated with 
rituximab, complement, or rituximab and complement, and cultured for 7 days. (D) FACS analysis for CD20-positive cells. Data is presented as per-
cent cell death of CD20-positive cells 7 days post-treatment (n = 5; untreated, rituximab treated, complement treated vs rituximab and complement 
treated cells: P < 0.001). (e) Cytotoxicity assays using untreated CD123-ENG, CD19-ENG, CD20.CD123-ENG, or rituximab and complement treated 
CD20.CD123-ENG T-cell lines as effectors and KG1a cells as targets. n = 3; assay performed in triplicates; untreated versus treated CD20.CD123-ENG 
T cells: P < 0.001; untreated CD20.CD123-ENG T cells versus CD19-ENG T cells: P < 0.001; treated CD20.CD123-ENG T cells versus CD19-ENG 
T cells: P = ns for all E:T ratios tested. (f) Mice engrafted with MOLM-13 were treated with 3x106 CD20.CD123-ENG/GFP.ffLuc T cells on Day 7 post-
leukemia injection. On Days 3–5 post-T-cell injection mice (n = 4) received 250 µg rituximab IP. Untreated mice (n = 3) served as controls. Quantitative 
bioluminescence imaging results (radiance = photons/sec/cm2/sr, mean and SD is plotted; P < 0.05 starting 2 days post-first dose of rituximab).
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Flow cytometry. Fluorochrome conjugated isotype controls, anti-CD123, 
anti-CD3, anti-CD4, anti-CD8, anti-CD33, anti-CD34, anti-CD45, anti-
CD45RA, and anti-CCR7 were purchased from BD Biosciences (San Jose, 
CA). CD123-specific scFvs were detected with an AlexaFluor 647-conju-
gated goat anti-mouse F(ab’)2 (Jackson Immunoresearch, West Grove, PA). 
Expression of mOrange was detected by FACS. Analysis was performed on 
at least 20,000 cells per sample using a FACSCalibur instrument and Cell 
Quest software (BD Biosciences).
Construction of retroviral vectors. The construction of the retroviral 
vector encoding the CD19-specific engager molecule has been previ-
ously reported.24 The CD123-specific engager molecule containing the 
immunoglobulin heavy-chain leader peptide, the CD123-specific scFv 
(26292),48 a short serine-glycine linker, and a CD3-specific scFV derived 
from OKT3 was synthesized by ThermoFisher Scientific (Grand Island, 
NY), and subcloned into pSFG-IRES-mOrange. The retroviral vector 
encoding full length CD20, a 2A sequence, and the CD123 engager 
molecule was generated by sublconing a minigene encoding CD20.2A.
CD123-ENG (ThermoFisher Scientific) into a pSFG retroviral vector. 
RD114-pseudotyped retroviral particles were generated as previously 
described.50 pCDH.CMV.hCD123.EF1.GFPpuro was generated by 
cloning a codon optimized cDNA (ThermoFisher Scientific) of human 
CD123 into the multiple cloning site (MCS) of pCDH.CMV.MCS.
EF1.GFPpuro. VSVG-pseudotyped lentiviral particles were generated 
according to the manufacturer’s instructions (System Biosciences, Inc., 
Mountain View, CA).
Generation of Engager-T cells. PBMCs were obtained from healthy donors 
under a Baylor College of Medicine Institutional Review Board (IRB)-
approved protocol, after informed consent was obtained in accordance to 
the Declaration of Helsinki. Cells were activated by stimulation on OKT3 
(CRL-8001, ATCC) and anti-CD28 (Becton Dickinson, Mountain View, 
CA) coated non-tissue culture-treated 24-well plates. Recombinant human 
interleukin (IL)-7 (10 ng/µl, R&D Systems, Minneapolis, MN) and IL-15 
(5 ng/µl, R&D Systems) were added to cultures on day 2, and the follow-
ing day cells were transduced with retroviral particles immobilized on 
RetroNectin (Clontech Laborotories, Mountain View, CA). T cells were 
maintained and expanded in the presence of IL-7 and IL-15. Cells were 
analyzed for expression of mOrange by FACS 5 to 7 days post-transduction.
CD123-ENG ELISA assay. Human recombinant CD123 (R&D Systems) was 
plated at 10 ng/well on a 96-well non- tissue culture treated plate. Media from 
ENG-T cells (CD123 and control: CD19) was plated and allowed to incu-
bate for 1 hour at room temperature (RT). Goat anti-mouse F(ab’) (Jackson 
Immunoresearch) was added, and incubated at RT for 1 hour. The plate was 
washed, and secondary anti-goat Horseradish Peroxidase (HRP) antibody 
(Jackson Immunoresearch) was added. After 1 hour incubation at RT, the 
plate was washed and developing agent was added (tetramethylbenzidine 
(TMB) substrate, Sigma-Aldrich). Absorbance was read at 450 nm. A stan-
dard curve was generated using recombinant CD123 T-cell ENG protein 
(custom synthesis, ThermoFisher Scientific; Supplementary Figure S2).
Cytokine secretion assay. ENG-T cells were plated with target cells at a 2:1 
ratio. Following 24 hours of culture, supernatant was harvested and ana-
lyzed for the presence of interferon (IFN) γ  or IL-2 using ELISA kits (R&D 
systems) according to the manufacturer’s instruction.
Chromium release assay. Target cells were labeled with 0.1 mCi 
51Chromium(Cr) and incubated with nontransduced (NT) or ENG-T cells 
at 40:1, 20:1, 10:1, and 5:1 effector to target (E:T) ratios for 4 hours. Targets 
in media alone or 1% Triton X-100 were used for spontaneous and maxi-
mum 51Cr release, respectively. Supernatants were collected and radioac-
tivity measured on a gamma counter. Mean percentage of specific lysis of 
triplicate samples was calculated as 100* (experimental release – spontane-
ous release)/(maximum release – spontaneous release).
Transwell assay. MOLM-13.GFP.ffLuc cells were plated in the bottom well 
of a 24-well tissue culture plate, and NT T cells, PBMCs, or media were 
added. Media, NT T cells, or ENG-T cells were added to the insert well (0.4 
µm pore, Corning, Corning, NY). After 24 hours, viable tumor cells were 
quantified by luciferase assay.
Primary leukemia sample cytotoxicity assay. Pediatric AML samples 
were obtained under a Baylor College of Medicine IRB approved protocol, 
after informed consent was obtained in accordance to the Declaration of 
Helsinki. The clinical flow laboratory uses a multi-parametric flow cyto-
metric assay with a set of 33 antibodies. The blast population of each sam-
ple was essentially identified using CD45 and side scatter, with almost all 
myeloid clones expressing dim to moderate CD45 compared to normal 
cell populations (lymphocytes and monocytes). The blast percentage in 
each specimen was calculated by gating on CD45/SSC-A along-with one 
or more distinct immunophenotypes expressed on the blasts. The blast 
percentage in the specimens used in this study ranged from 33–90%. Cells 
were incubated with media alone or ENG-T cells at indicated E:T ratios for 
6 hours, then plated in MethoCult (Classic) media (Stemcell Technologies, 
Vancouver, BC, Canada) per manufacturer’s instruction. After 10–14 days, 
media was resuspended with dilution into RPMI and cells were manually 
counted with a hemocytometer and trypan blue exclusion.
CFU assays. Bone marrow and cord blood units were obtained under a 
Baylor College of Medicine IRB approved protocol in accordance to the 
Declaration of Helsinki. Bone marrow or cord blood mononuclear cells 
(BMMCs, CBMCs) were isolated by standard density gradient centrifu-
gation and cyropreserved. For CFU assays, CBMCs or BMMCs were 
incubated with media alone or ENG-T cells at indicated E:T ratios for 6 
hours, then plated in MethoCult (Classic) media (Stemcell Technologies, 
Vancouver, BC, Canada) per manufacturer’s instruction. After 10–14 days, 
colonies were counted.
Complement-dependent cytotoxicity assay. T cells transduced with 
CD20.CD123-ENG were labelled with 0.1 mCi 51Cr and then treated with 
10 µg/ml rituximab (Roche, San Francisco, CA), 10% baby rabbit comple-
ment (Cedarlane Labs, Burlington, NC), or 10 µg/ml rituximab and 10% 
baby rabbit complement. Cells were incubated for 4 hours. Targets in 
media alone or 1% Triton X-100 were used for spontaneous and maximum 
51Cr release, respectively. Supernatants were collected and radioactivity 
measured on a gamma counter. Mean percentage of specific lysis of tripli-
cate samples was calculated as 100* (experimental release – spontaneous 
release)/(maximum release – spontaneous release).
FACS-based cytotoxicity assay. CD20.CD123-ENG T cells were treated 
with 10 µg/mL rituximab, 10% baby rabbit complement, or 10 µg/ml 
rituximab and 10% baby rabbit complement and incubated for 2 hours. 
Following incubation, the remaining T cells were expanded for one week 
in IL-7 and IL-15 before determining the presence of CD20-positive cells 
by FACS analysis.
Xenograft NSG model. All animal experiments were performed on a pro-
tocol approved by the Baylor College of Medicine Institutional Animal 
Care and Use Committee in accordance to the American Association 
for Laboratory Animal Science. NSG mice (NOD.Cg- Prkdcscid/
Il2rgtm1Wjl/SzJ, Bar Harbor, ME) were sub-lethally irradiated with 200 
cGy 24 hours prior to tail vein injection with 5x104 MOLM-13.GFP.ffLuc 
cells. Mice were treated with ENG-T cells intravenously at day 7 or at 
days 7 and 14 days after MOLM-13.GFP.ffLuc injection. Untreated mice 
served as controls. In experiments designed to track T-cell expansion and 
persistence in vivo, CD123-ENG T cells were modified with GFP.ffLuc. 
Unmodified MOLM-13 AML cells were used as described. To test the abil-
ity of rituximab to deplete T cells in vivo, mice were sub-lethally irradiated 
with 200 cGy 24 hours prior to tail vein injection with 5 × 104 MOLM-
13 cells. Mice received on day 7 post-MOLM-13 injection 3 × 106 CD20.
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CD123-ENG-T cells. CD20.CD123-ENG T cells also expressed GFP.ffLuc. 
On day 3 post-T-cell injection, mice received 250 µg of rituximab IP for 
3 consecutive days. Untreated mice served as controls. Bioluminescent 
imaging was performed on an IVIS system (IVIS, Xenogen, Alameda, CA) 
as previously described.51 Euthanasia was performed at prior determined 
time points or when animals met euthanasia criteria in accordance with 
Baylor College of Medicine’s Center for Comparative Medicine.
Statistical analysis. GraphPad Prism 5 software (GraphPad software) was 
used for statistical analysis. Measurement data were presented as mean ± 
standard error. For comparison between two groups, two-tailed t-test was 
used. For comparisons of three or more groups, the values were analyzed 
by one-way analysis of variance with Bonferroni’s post-test. For the mouse 
experiments, survival, determined from the time of tumor cell injection, 
was analyzed by the Kaplan–Meier method and by the log-rank test.
SUPPLEMENTARY MATERIAL
Figure S1. CD123-ENG T cells exhibit similar T-cell phenotype to 
non-transduced, ex-vivo expanded T cells.
Figure S2. Standard curve of developed ELISA to detect CD123 T-cell 
ENG protein.
Figure S3. Myeloid leukemia cell lines express CD123.
Figure S4. Human T-cell infiltration into liver of NSG mice treated 
with CD123-ENG T cells.
Figure S5. Generation of CD20.CD123-ENG T cells.
Figure S6. Selection and in vitro elimination of CD20.CD123-ENG 
T cells.
Figure S7. Expression of inducible caspase 9 (iC9) in CD123 ENG T 
cells is toxic.
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